Willem Lybaert

Medisch Oncoloog VITAZ - UZA Belgium. Board member and Secretary BSMO, Vice-President NETwerk ENETS CoE, President VWHHT.

[Willem Lybaert @WLybaert]

@W0rld2026 Amazing Lake🥰🥰

[WORLD 2026 🌊 @W0rld2026]

Lake como, Italy 🇮🇹

[𝕏 Travels, Hotels and Resorts @em3dia]

🇮🇹 Welcome to Positano, a destination that looks so spectacular it frequently feels like a painting.

This incredible cliffside village tucked along Italy’s sun-drenched Amalfi Coast is world-famous for its unique, vertical cascade of colourful Mediterranean houses that seem to stack effortlessly on top of one another.

Below the houses lie beautiful pebbled beaches, all connected by a labyrinth of steep, winding streets lined with bougainvillaea.

Without question, the views in Positano are truly unbeatable. The architecture is masterfully designed so that almost every vantage point faces the sea. Stepping out onto your private hotel terrace in the morning to take in the sweeping expanse of the deep blue ocean and rugged cliffs is an experience that stays with you long after your holiday ends.

🎥 loloschackman | IG

[Thor Halfdanarson @OncoThor]

Trying to explain somatostatin receptor PET imaging in as few words as possible for my talk at ENDO2026 next weekend... I have found my previous slides to be too wordy (no surprise to anyone who knows me...😅).

How are these for an explanation? My own slide first, then ChatGPT with a prettier slide but I think they complement each other

Nuclear Medicine folks: Feel free to make fun of this... I am just a simple chemotherapist... 🤣

[Erman Akkus @Erman_Akkus]

🏥T4, MRF, CRM in rectal cancer for medical oncologists

✅All related but different concepts
➡️T4b but MRF- (e.g. upper third tm)
➡️MRF by MRI, CRM by pathological
➡️MRF- but CRM+ (e.g. technically hard surgery)

PS: prepared by AI. Surgeon, pathologist, radiologist colleagues may correct if wrong

#cancer #oncology #MedX #rectal #GI @OncoAlert

[OncLive.com @OncLive]

🇪🇺 CHMP has recommended camizestrant plus a CDK4/6 inhibitor for ESR1-mutated HR+/HER2– advanced breast cancer based on data from the phase 3 SERENA-6 trial.

Full details ➡️: https://t.co/m65E4D4JnM

#bcsm #oncology

[BJS @BJSurgery]

Surgical management of small intestinal neuroendocrine tumours
➡️ https://t.co/IB3jb3wXWQ

I TNE dell’intestino tenue richiedono un approccio chirurgico specifico, in grado di conciliare controllo oncologico, preservazione della funzione intestinale, sollievo dei sintomi e qualità di vita a lungo termine
Questa Commission BJS sottolinea l’importanza di una presa in carico multidisciplinare, con expertise nei TNE, e la necessità di strategie più standardizzate e basate sulle evidenze lungo tutto il percorso perioperatorio

Lavoro di Julie Hallet , Massimo Falconi , Sean Bennet , Andrea Frilling , Alexandra Gangi , Sébastien Gaujoux , Rodney Pommier , Emilio Bertani , Gabriela A Buerba , Jennifer Chan , Callisia N Clarke , Sophie Deguelte , Jaydira Del Rivero , Els Nieveen van Dijkum , Teodora Dumitra , Dilmurodjon Eshmuminov , Anton Engelsman , Francesca Fermi , Simona Grozinsky-Glasberg , James R Howe , Angela Lamarca , Léamarie Meloche-Dumas , Frédéric Mercier , Sten Myrehaug , Julie Perinel , Charles De Ponthaud , Ville Sallinen , Yun Song , Heather Stuart , Eva T Janson , Pascale Tinguely , Francesca Tozzi , Tessa van Ginhoven , Susanne Warner , Kjetil Soreide , @spartelli

#SoMe4Surgery #MedTwitter #SurgEd #Surgery @RCPSGTrainees @aecirujanos @SEIQuirurgica @iss_sic #MedicalTechniques @BJSAcademy @young_bjs @BJSOpen @evanscolorectal @robhinchliffe1 @bplwijn @MalinASund @nfmkok @TejedorPat @paulo_sutt @PVaughanShaw @JJEarnshaw @juliomayol @ksoreide #some4UGI #uppergi #esophagealcancer #gastriccancer #reflux @ISDE_net @Augishealth @roux_group @T4UGIS @SARONG_Trial @YoungIFSO #bariatricsurgery

[Mambo Italiano @mamboitaliano__]

🚨 “LipaLeaks”

First images dropping from Villa Valguarnera

The breathtaking location of Dua Lipa’s wedding

Sicily, Italy 🇮🇹

[MV Chandrakanth @ChandrakanthMv]

TRIPLE-NEGATIVE BREAST CANCER #ASCO2026

A clear theme emerged this year:

From immunotherapy-driven gains in early disease to ADC-driven advances in metastatic TNBC.

Key takeaways:

🔹 KEYNOTE-522: Durable 7-year survival benefit

🔹 ASCENT-04: ADC + IO moves into 1L PD-L1+ mTNBC

🔹 ASCENT-03: SG benefit observed across biomarker groups

🔹 TROPION-Breast02: Dato-DXd validates the TROP2 ADC class

🔹 PANKU-BREAST02: Bispecific ADCs represent the next wave of innovation

ASCO 2026 reinforced the transition from conventional chemotherapy toward ADC-based precision therapy in TNBC.

#TNBC #BreastCancer #ASCO #Oncology #ADC #SacituzumabGovitecan #DatoDXd #MVOnco

[Dr Himanshu batra @drhimanshubatra]

If ASCO 2026 had an immunotherapy theme, it would be this: 🧪💉

🧬Precision over noise.
💊Durability over excitement.
🩺Strategy over randomness.

4 trials. 3 tumor groups. 1 clear message from ASCO 2026:
Immunotherapy is entering its smarter era.

RUBY
NRG-GY018
EMERALD-3
STELLAR-303

Durability. Precision. Combinations that matter.

#ASCO26 #Immunotherapy #Oncology #Medtwitter @ASCO @JCO_ASCO @JCOGO_ASCO @OncUpdates @oncodaily @OncoDailyIO @AmericanCancer @sitcancer @NatureCancer

[Dr Rupam Manna MD @DrRupamOncology]

Endocrine Resistance in HR+ Breast Cancer: PI3K–AKT–mTOR Pathway & Targeted Therapies (2025–2026)

Understanding the mechanisms of endocrine resistance is critical for optimizing treatment in HR+ metastatic breast cancer.

This infographic covers:

• Key mechanisms driving resistance (PIK3CA, AKT1, PTEN alterations, ESR1 mutations)
• Current targeted therapy options: Capivasertib, Inavolisib, Alpelisib & Everolimus
• Biomarker-driven treatment selection
• Updated preferred sequencing in 2025–2026
• High-yield clinical pearls for exam and practice

A practical, evidence-based resource for medical oncologists, fellows, and residents.

Save this for your next HR+ breast cancer case.

#BreastCancer #EndocrineResistance #PI3K #AKT #mTOR #MedicalOncology #DrRupamManna

[Dr Rupam Manna MD @DrRupamOncology]

🧑‍⚕️ Two patients. Two different stories. One important question:

Which ADC should we choose next in metastatic breast cancer —
Sacituzumab Govitecan or Datopotamab Deruxtecan?

This infographic compares both ADCs using real clinical scenarios (HR+/HER2-negative vs TNBC) based on latest trial data.

Save this for your next case discussion 👇

[Dr Rishabh Jain @DrRishabhOnco]

A 4-year survival tail in ES-SCLC?

ASTRUM-005 final analysis says yes.

🫁 First-line ES-SCLC
Serplulimab + carbo/etop vs placebo + chemo
Phase III | n=585 | JAMA Oncology

Key numbers:
⚡ OS: 15.8 vs 11.1 mo
📉 HR 0.60, p<0.001
⏳ 4-year OS: 21.9% vs 7.2%
📊 PFS: 5.8 vs 4.3 mo
📈 ORR: 68.9% vs 58.7%

Safety:
Grade ≥3 treatment-related AEs: 35.0% vs 29.1%
No new safety signals.

My take:
In ES-SCLC, where durable survivors are rare, the 4-year OS signal is the real story.

Serplulimab + platinum-etoposide looks like a strong first-line standard option.

🔖 Save this for ES-SCLC updates.

📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #LCSM #SCLC
@OncoAlert @myesmo @esmo_open @asco

[Willem Lybaert @WLybaert]

@mamboitaliano__ Nice place for a wedding…Sicilia is amazing beautiful and soooo dolce vitaaaaa❤️❤️

[Mambo Italiano @mamboitaliano__]

🚨 Dua Lipa is straight-up rewriting the celebrity wedding game in Italy 🇮🇹

No more stiff, staged, picture-perfect productions

Spontaneity, Sicily streets, dancing like nobody’s watching, real smiles &amp; raw energy

This is exactly how it should be done!

Long live the couple ❤️‍🔥

[Dr Rupam Manna MD @DrRupamOncology]

📌 High-Yield Immunotherapy Concept Every Oncologist & Resident Must Master

**ICI Resistance Mechanisms**
(Primary & Acquired Resistance to PD-1 / PD-L1 / CTLA-4 Inhibitors)

Complete visual masterclass in one frame:
✅ Definition: Primary vs Acquired resistance
✅ Tumor-intrinsic mechanisms (MHC-I/B2M loss, low TMB, WNT/PI3K pathways)
✅ Tumor Microenvironment (Tregs, MDSCs, TGF-β, hypoxia)
✅ Checkpoint redundancy (LAG-3, TIM-3, TIGIT)
✅ T-cell exhaustion & immune desert
✅ Host factors (Microbiome dysbiosis, steroids, antibiotics)
✅ Clinical pearls (MSI-H advantage + rational combinations)

“Understanding mechanisms of ICI resistance helps in selecting rational combinations and improving outcomes.”

Save it. Share it. Use it in clinic & viva.

Next topic dropping soon: **NTRK Inhibitors – Short Notes**

Dr Rupam Manna
@DrRupamOncology

#ICIResistance #Immunotherapy #PD1 #CancerImmunology #OncoViva #MedicalEducation #Oncology #VivaPrep

[Dr Rupam Manna MD @DrRupamOncology]

🧔‍♂️ Meet Mr. Sharma — 58 years old with recurrent tongue cancer and lung metastases.

His case raises one of the most common dilemmas in head & neck oncology:

“What should be the first-line systemic therapy in recurrent/metastatic HNSCC?”

This infographic breaks it down using a practical, story-based approach based on KEYNOTE-048:

✅ How to decide between Pembrolizumab alone vs Pembrolizumab + Chemo
✅ Role of PD-L1 CPS (≥20 vs 1–19 vs <1)
✅ When to add chemotherapy for rapid response
✅ 5-FU free regimens (increasingly used)
✅ Management in frail/elderly patients
✅ Clear one-minute exam algorithm

High-yield for Medical Oncology residents and practicing oncologists.

Save this for your next HNSCC case discussion 👇

#HNSCC #HeadAndNeckCancer #KEYNOTE048 #Immunotherapy #MedicalOncology #ExamPrep #DrRupamManna

[Filip Lardon @FilipLardon]

Het krijgen van #kanker is vaak ‘brute pech’. Maar de vooruitgang in kankerbehandelingen is aanzienlijk. Mijn bijdrage @HLN_BE https://t.co/NAi0gmXcrQ

[Mambo Italiano @mamboitaliano__]

Recommendation of the Day ✨

“Bahia Porto Cesareo”

Puglia, Italy 🇮🇹

And that’s all you need…

[Willem Lybaert @WLybaert]

@mamboitaliano__ Porto Cesareo è molto carino, certamente da visitare quando sei in Puglia❤️❤️